Eribulin effective for earlier treatment of metastatic breast cancer
the ONA take:
According to a new study published in the Journal of Clinical Oncology, researchers have found eribulin is active and well tolerated as first-, second-, or third-line therapy in patients with metastatic breast cancer.
For the study, researchers sought to determine the activity of eribulin as an early treatment for metastatic breast cancer.
For the phase 3 study, researchers randomly assigned 1,099 women with metastatic breast cancer who had previously been treated with an anthracycline or a taxane to receive either capecitabine or eribulin as first-, second-, or third-line therapy for metastatic breast cancer.
Results showed that there was no statistical difference in overall survival between capecitabine and eribulin. In addition, a subset analysis found that eribulin may be especially active in those with triple negative metastatic breast cancer, a type of breast cancer that is particularly difficult to treat because it does not respond to hormonal therapy or HER2-targeted therapies.
The findings suggest that eribulin may have a role earlier in the course of the treatment of metastatic breast cancer.
Eribulin is active and well tolerated as first-, second-, or third-line therapy in patients with metastatic breast cancer.
- Neurotoxicity After CAR T-cell Therapy May Be Associated With Endothelial Activation
- Navigation Programs Most Effective in Increasing Follow-up Colonoscopy
- New Class of Clinical Trial Enhances Research on Cancer Care Delivery
- Specialized Interventions Reduce Aberrant Opioid Behaviors in Cancer Patients
- Nivolumab Provides Better Long-Term Efficacy Compared With Docetaxel in NSCLC
- Anticancer Properties of The Probiotic Kefir: A Review
- Navigating the Transition From Treatment to Breast Cancer Survivor
- Combining Radiation, Immunotherapy: An Emerging Challenge for Oncology Nursing
- Naldemedine Effective for Opioid-Induced Constipation in Cancer Pain
- Disruptions to Circadian Rhythm Linked to Prostate Cancer Surgery Regret
- Case Report of a KIT-mutated Melanoma Patient With an Excellent Response to Apatinib and Temozolomide Combination Therapy
- Novel Predictive Model More Effectively Identifies Risk for Lung Cancer
- Long-Term Eltrombopag Increases Platelet Counts, Decreases Bleeding in ITP
- Overall Survival Increase for Melanoma Brain Metastases
- Prophylactic Prochloperazine Ineffective for Opioid-induced Nausea/Vomiting in Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|